Approval Year
| Substance Class |
Mixture
Created
by
admin
on
Edited
Sat Dec 16 15:00:27 GMT 2023
by
admin
on
Sat Dec 16 15:00:27 GMT 2023
|
| Record UNII |
S134V96RPQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C574
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
||
|
FDA ORPHAN DRUG |
312610
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
||
|
NCI_THESAURUS |
C20401
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ROZROLIMUPAB
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
PRIMARY | |||
|
C152271
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
PRIMARY | |||
|
909402-77-3
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
PRIMARY | |||
|
DB05209
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
PRIMARY | |||
|
UU-166
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107859
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
PRIMARY | |||
|
S134V96RPQ
Created by
admin on Sat Dec 16 15:00:27 GMT 2023 , Edited by admin on Sat Dec 16 15:00:27 GMT 2023
|
PRIMARY |
All of the following components must be present:
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET->LIGAND |
proposed that anti-D Ig’s cause IgG antibody coating and opsonization of RBC’s, leading to FcR-mediatied binding to macrophages and other phagocytic cells. Used as a decoy to protect antibody-coated platelets.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
Agent Modifications
| Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
|---|---|---|---|---|---|
| IMMUNOLOGICAL | BLOOD GROUP RH(D) POLYPEPTIDE | 16YYC73841 |